Literature DB >> 18089876

Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women.

Ann G Schwartz1, Angela S Wenzlaff, Geoffrey M Prysak, Valerie Murphy, Michele L Cote, Sam C Brooks, Debra F Skafar, Fulvio Lonardo.   

Abstract

PURPOSE: Estrogen receptor (ER) expression in lung tumors suggests that estrogens may play a role in the development of lung cancer. We evaluated the role of hormone-related factors in determining risk of non-small-cell lung cancer (NSCLC) in women. We also evaluated whether risk factors were differentially associated with cytoplasmic ER-alpha and/or nuclear ER-beta expression-defined NSCLC in postmenopausal women. PATIENTS AND METHODS: Population-based participants included women aged 18 to 74 years diagnosed with NSCLC in metropolitan Detroit between November 1, 2001 and October 31, 2005. Population-based controls were identified through random digit dialing, matched to patient cases on race and 5-year age group. Interview data were analyzed for 488 patient cases (241 with tumor ER results) and 498 controls.
RESULTS: Increased duration of hormone replacement therapy (HRT) use in quartiles was associated with decreased risk of NSCLC in postmenopausal women (odds ratio = 0.88; 95% CI, 0.78 to 1.00; P = .04), adjusting for age, race, pack-years, education, family history of lung cancer, current body mass index, years exposed to second-hand smoke in the workplace, and obstructive lung disease history. Among postmenopausal women, ever using HRT, increasing HRT duration of use in quartiles, and increasing quartiles of estrogen use were significant predictors of reduced risk of NSCLC characterized as ER-alpha and/or ER-beta positive. None of the hormone-related variables were associated with nuclear ER-alpha- or ER-beta-negative NSCLC.
CONCLUSION: These findings suggest that postmenopausal hormone exposures are associated with reduced risk of ER-alpha- and ER-beta-expressing NSCLC. Understanding tumor characteristics may direct development of targeted treatment for this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18089876     DOI: 10.1200/JCO.2007.13.3975

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  68 in total

1.  Targeting the estrogen pathway for the treatment and prevention of lung cancer.

Authors:  Timothy F Burns; Laura P Stabile
Journal:  Lung Cancer Manag       Date:  2014-02-01

2.  Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women.

Authors:  Susan E Olivo-Marston; Leah E Mechanic; Steen Mollerup; Elise D Bowman; Alan T Remaley; Michele R Forman; Vidar Skaug; Yun-Ling Zheng; Aage Haugen; Curtis C Harris
Journal:  Carcinogenesis       Date:  2010-08-20       Impact factor: 4.944

3.  Reproductive and hormonal factors and the risk of nonsmall cell lung cancer.

Authors:  Cari L Meinhold; Amy Berrington de González; Elise D Bowman; Alina V Brenner; Raymond T Jones; James V Lacey; Christopher A Loffredo; Donna Perlmutter; Sara J Schonfeld; Glenwood E Trivers; Curtis C Harris
Journal:  Int J Cancer       Date:  2011-03-15       Impact factor: 7.396

4.  The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer.

Authors:  Nadiyah Kazmi; Diana C Márquez-Garbán; Lilia Aivazyan; Nalo Hamilton; Edward B Garon; Lee Goodglick; Richard J Pietras
Journal:  Lung Cancer Manag       Date:  2012-12

5.  Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women.

Authors:  Michele L Cote; Wonsuk Yoo; Angela S Wenzlaff; Geoffrey M Prysak; Susan K Santer; Gina B Claeys; Alison L Van Dyke; Susan J Land; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2009-01-27       Impact factor: 4.944

Review 6.  Estrogen receptors as the novel therapeutic biomarker in non-small cell lung cancer.

Authors:  Hideki Kawai
Journal:  World J Clin Oncol       Date:  2014-12-10

7.  COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.

Authors:  Alison L Van Dyke; Michele L Cote; Geoffrey M Prysak; Gina B Claeys; Angie S Wenzlaff; Valerie C Murphy; Fulvio Lonardo; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2008-05-02       Impact factor: 4.944

8.  Reproductive factors and risk of lung cancer in female textile workers in Shanghai, China.

Authors:  Lisa G Gallagher; Karin A Rosenblatt; Roberta M Ray; Wenjin Li; Dao L Gao; Katie M Applebaum; Harvey Checkoway; David B Thomas
Journal:  Cancer Causes Control       Date:  2013-04-13       Impact factor: 2.506

9.  Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial.

Authors:  Rowan T Chlebowski; Heather Wakelee; Mary Pettinger; Thomas Rohan; Jingmin Liu; Michael Simon; Hilary Tindle; Catherine Messina; Karen Johnson; Ann Schwartz; Margery Gass; Jean Wactawski-Wende
Journal:  Clin Lung Cancer       Date:  2015-10-22       Impact factor: 4.785

10.  Dietary boron and hormone replacement therapy as risk factors for lung cancer in women.

Authors:  S Mahabir; M R Spitz; S L Barrera; Y Q Dong; C Eastham; M R Forman
Journal:  Am J Epidemiol       Date:  2008-03-14       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.